Authors
Latest:
Phase I Dose-Escalation Results for Marizomib in Newly Diagnosed GlioblastomaDaniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.
Latest:
Current Options for Frontline Treatment of CLLDanielle Brander, MD, discusses the current treatment landscape in the frontline setting for patients with chronic lymphocytic leukemia.
Latest:
Expert Highlights Changes in the Treatment Landscape of RCCPatients with renal cell carcinoma have seen a change in standard of care as novel therapies and combinations are quickly approved, says Toni K. Choueiri, MD.
Latest:
Acalabrutinib Improves Long-Term PFS in Patients With High-Risk CLLDanielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Latest:
Safety and Efficacy of Combination Targeted Therapy and RadiotherapyA review of currently published clinical trials examining the combinaiton of radiation therapy with commonly used targeted agents, such as vascular endothelial growth factor inhibitors, endothelial growth factor receptor inhibitors, and inhibitors of the PI3K/Akt/mTOR pathway.
Latest:
FDA Lifts Partial Clinical Hold on Phase 1 Studies of PRS-343 for Solid TumorsThe FDA has lifted a partial clinical hold on the phase 1 clinical trials of PRS-343 for solid tumors.
Latest:
Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCCDanny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Latest:
Findings for Cemiplimab in Advanced or Recurrent Cervical CancerDanny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
Latest:
Regorafenib Shows High Anti-Tumor Activity as Monotherapy in Advanced, Pre-Treated Thymic CancerAs part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.
Latest:
Dr. Darren Feldman on Treating Patients Who Develop Neutropenic Fever​Darren Feldman, MD, assistant attending physician for the Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how to properly treat neutropenic fever as a toxicity stemming from chemotherapy treatment.
Latest:
Expected Findings of the SWOG S1505 Trial in Pancreatic CancerDavendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Latest:
The Inadequacy of the Current Standard of Care for GlioblastomaDavid A. Reardon, MD, clinical director, center for neuro-oncology, Dana-Farber Cancer Institute, discusses the inadequacy of the current standard of care in glioblastoma (GBM).
Latest:
Guidelines Consider Use of Targeted Therapies in Colorectal CancerThe use of targeted therapies in colon cancer has become increasingly important, with several options available for clinicans to choose between. In a review of recent updates incorporating molecularly targeted therapy use in the National Comprehensive Cancer Network guidelines, the evidence for these new recommendations are detailed in support of their use in patients with colon cancer.
Latest:
Novel Treatment Approaches in Relapsed/Refractory Mantle Cell LymphomaManagement of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.
Latest:
Nanovesicles as Targeted Therapy for Lung CancerAvailable therapies for patients with lung cancer are associated with a number of significant toxicities that must be effectively managed by oncologists.
Latest:
Dr. Metz on Somatostatin Analogs and Emerging Agents in NETs LandscapeDavid C. Metz, MD, PhD, associate chief for Clinical Affairs, Gastrointestinal Division, Penn Medicine, University of Pennsylvania, discusses the utility of somatostatin analogs and emerging agents in the landscape of neuroendocrine tumors (NETs).
Latest:
Nivolumab Shows Promise Versus Docetaxel for NSCLC in Checkmate 057 TrialDavid Carbone, MD, PhD, professor, internal medicine, College of Medicine Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute at Ohio State University Medical Centerdiscusses the Checkmate 057 trial, which evaluates Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Latest:
PD-L1 Expression in Non-Clear Cell Renal Cell CancerDavid F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Latest:
Preparing Cancer Centers for Outpatient CAR T-cell AdministrationDavid G. Maloney, MD, PhD, reviews the protocols and infrastructure necessary to deliver chimeric antigen receptor T-cell therapy to patients receiving treatment in the outpatient setting.
Latest:
Strategies for Overcoming <em>KRAS</em> Mutations in Lung CancerDavid Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.
Latest:
KEYNOTE-062 Highlights Role of Pembrolizumab in Gastric/GEJ Cancer SubtypesDavid H. Ilson, MD, PhD, discusses the current role of pembrolizumab in patients with gastric cancer or gastroesophageal junction adenocarcinoma based on the results from the KEYNOTE-062 trial.
Latest:
What’s Next With Next-Generation BRAF Inhibitors?Targeted therapy for patients with activating BRAF mutations has demonstrated the potential for personalized medicine in patients with metastatic melanoma. Initial study results were promising and dramatic.
Latest:
Efficacy Results for LOXO-101 in TRK Fusion CancersDavid Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Latest:
Exploring Current and Upcoming Therapies for Hepatocellular CarcinomaDavid J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
Latest:
Dr. Stewart on the Impact of Delaying Approval on Overall SurvivalDavid J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival.
Latest:
Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHLDavid J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
Latest:
The Need to Study Tissue BiomarkersDavid L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
